Generic Visudyne Availability
Last updated on Jun 11, 2025.
Visudyne is a brand name of verteporfin, approved by the FDA in the following formulation(s):
VISUDYNE (verteporfin - injectable;injection)
-
Manufacturer: BAUSCH LOMB IRELAND
Approval date: April 12, 2000
Strength(s): 15MG/VIAL [RLD]
Is there a generic version of Visudyne available?
No. There is currently no therapeutically equivalent version of Visudyne available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Visudyne. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
More about Visudyne (verteporfin)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- Drug class: miscellaneous antineoplastics
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Related/similar drugs
Vabysmo
Vabysmo eye injection is used to treat eye diseases neovascular (wet) age-related macular ...
Eylea
Eylea is used to treat neovascular (wet) age-related macular degeneration (AMD), macular edema ...
Izervay
Izervay (avacincaptad pegol) is used for treating geographic atrophy (GA) due to age-related ...
Syfovre
Syfovre (pegcetacoplan) treatment for geographic atrophy (GA) a form of dry age-related macular ...
Eylea HD
Eylea HD is used to treat neovascular (wet) age-related macular degeneration (AMD), diabetic ...
Lucentis
Lucentis is used to treat the wet form of age-related macular degeneration. Learn about side ...
Pavblu
Pavblu (aflibercept-ayyh) is a biosimilar to Eylea that may be used to treat the following eye ...
Yesafili
Yesafili (aflibercept-jbvf) is an interchangeable biosimilar to Eylea that may be given by ...
Faricimab ophthalmic
Faricimab ophthalmic is used for diabetic macular edema, macular degeneration, macular edema ...
Ranibizumab ophthalmic
Ranibizumab ophthalmic is used for diabetic macular edema, diabetic retinopathy, macular ...
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.